Soluble ST2 as a Biomarker for Detecting Stable Heart Failure With a Normal Ejection Fraction in Hypertensive Patients

Wang, Yi Chih; Yu, Chih Chieh; Chiu, Fu-Chun; Tsai, Chia Ti; Lai, Ling‐Ping; Hwang, Juey Jen; Lin, Jiunn Lee

doi:10.1016/j.cardfail.2013.01.010

Cited by 80 publications

(62 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23,48,105,109,110,205,206 A number of studies have demonstrated that Gal-3 is increased in HFpEF and predicts worse outcomes in this population, but concentrations tend to be lower than in HFrEF. 110 In patients with HFpEF, Gal-3 >17.8 ng/mL indicates low risk; Gal-3 of 17.9 to 25.9 ng/mL, intermediate risk; and Gal-3 >25.9 ng/mL, higher risk.…”

Section: Markers Of Inflammation and Immune Signalingmentioning

confidence: 99%

Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association

Chow¹,

Maisel²,

et al. 2017

View full text Add to dashboard Cite

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and prognostic tool for the diagnosis and management of heart failure (HF). More recent evidence suggests that natriuretic peptides along with the next generation of biomarkers may provide added value to medical management, which could potentially lower risk of mortality and readmissions. The purpose of this scientific statement is to summarize the existing literature and to provide guidance for the utility of currently available biomarkers. Methods: The writing group used systematic literature reviews, published translational and clinical studies, clinical practice guidelines, and expert opinion/statements to summarize existing evidence and to identify areas of inadequacy requiring future research. The panel reviewed the most relevant adult medical literature excluding routine laboratory tests using MEDLINE, EMBASE, and Web of Science through December 2016. The document is organized and classified according to the American Heart Association to provide specific suggestions, considerations, or contemporary clinical practice recommendations. Results: A number of biomarkers associated with HF are well recognized, and measuring their concentrations in circulation can be a convenient and noninvasive approach to provide important information about disease severity and helps in the detection, diagnosis, prognosis, and management of HF. These include natriuretic peptides, soluble suppressor of tumorgenicity 2, highly sensitive troponin, galectin-3, midregional proadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others. There is a need to further evaluate existing and novel markers for guiding therapy and to summarize their data in a standardized format to improve communication among researchers and practitioners. Conclusions: HF is a complex syndrome involving diverse pathways and pathological processes that can manifest in circulation as biomarkers. A number of such biomarkers are now clinically available, and monitoring their concentrations in blood not only can provide the clinician information about the diagnosis and severity of HF but also can improve prognostication and treatment strategies.

show abstract

Section: Markers Of Inflammation and Immune Signalingmentioning

confidence: 99%

Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association

Chow¹,

Maisel²,

et al. 2017

View full text Add to dashboard Cite

show abstract

“…21 sST2 did not provide independent prognostic information for sudden cardiac death (n=42) after adjustment for clinical variables and biomarkers Abbreviations: ACE, angiotensin-converting enzyme; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CI, confidence interval; Copeptin, C-terminal part of the arginine vasopressin prohormone; CRP, C-reactive protein; cTnI, cardiac troponin I; cTnT, cardiac troponin T; eGFR, estimated glomerular filtration rate; GDF-15, growth differentiation factor-15; GRACE score, Global Registry of Acute Coronary Events risk score; HR,…”

Section: Arterial Hypertensionmentioning

confidence: 97%

Soluble ST2 in heart failure

Dieplinger

Mueller

2015

Clinica Chimica Acta

124

View full text Add to dashboard Cite

“…4 ST2 proved to be superior to Gal-3, as biomarkers characterizing myocardial fibrosis in CHF. In a head-to-head evaluation of 3 biomarkers (sST2, growth differentiation factor (GDF)-15, and highly-sensitive troponin T -hsTnT) in 151 patients with CHF, the only biomarker that showed predictive power in foreseeing changes in the left ventricular function, was sST2.…”

Section: Soluble St2mentioning

confidence: 95%

Recent Advances in Biomarker Discovery — from Serum to Imaging-based Biomarkers for a Complex Assessment of Heart Failure Patients

Chiotoroiu

Buicu

Neagu

et al. 2016

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

Over the last years, a vast majority of serum biomarkers and imaging techniques have been used alone or combined in the diagnosis, management and prognosis of numerous pathologies. This review provides a brief insight into the novelties from the last 6 years (2010-2016) regarding serum and imaging markers in heart failure (HF). New information about natriuretic peptides (NPs), soluble ST2 (Sst2), growth differentiation factor 15 (GDF-15), myeloperoxidase (MPO), C-reactive protein (CRP), procalcitonin (PCT), troponins (Tns), myoglobin (Mb), galectin-3 (Gal-3), micro ribonucleic acids (microRNAs) and long non-coding ribonucleic acids (IncRNAs), copectin and cardiac magnetic resonance (CMR) measurements were summarized in this review in order to guide the practitioner.

show abstract

Soluble ST2 as a Biomarker for Detecting Stable Heart Failure With a Normal Ejection Fraction in Hypertensive Patients

Cited by 80 publications

References 25 publications

Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association

Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association

Soluble ST2 in heart failure

Recent Advances in Biomarker Discovery — from Serum to Imaging-based Biomarkers for a Complex Assessment of Heart Failure Patients

Contact Info

Product

Resources

About